CAMBRIDGE, Mass. & LOS ANGELES--(BUSINESS WIRE)--Lotus Tissue Repair, Inc. and the University of Southern California (USC) today announced an exclusive license to the patent portfolio for the proprietary recombinant collagen Type VII (rC7) technology invented by USC professors of dermatology, Mei Chen, Ph.D., and David Woodley, M.D. This license includes their groundbreaking work in dystrophic epidermolysis bullosa (DEB), an orphan disease that causes devastating skin blisters, morbidity and early mortality, as well as their rC7 research in accelerated chronic wound healing and bone repair indications.
